Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line Immunotherapy

NCT06313541 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

146

Enrollment

OTHER

Sponsor class

Conditions

NSCLC Stage IV

Interventions

RADIATION: SBRT or LDRT
DRUG: PD-1/PD-L1 inhibitor combined with platinum-based chemotherapy

Sponsor

Fudan University